Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180325 | 1.00 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3SMN1; SMN2 | |
| SCHEMBL2176160 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL30786879 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2322439 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2176161 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2178238 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2154692 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 | |
| SCHEMBL2154689 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 | |
| SCHEMBL15474100 | 0.86 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 | |
| SCHEMBL13731760 | 0.86 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617706-B1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD (CN) | 2017-09-06 | — | — | EP | claimed |
| EP-2617706-B1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | ANHUI NEW STAR PHARMACEUTICAL DEV CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9682918-B2 | intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVLOPMENT CO., LTD. (CN) | 2017-06-20 | — | — | US | disclosed |
| US-9682918-B2 | intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVLOPMENT CO., LTD. (CN) | 2017-06-20 | — | — | US | disclosed |
| US-9556107-B2 | Intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-9556107-B2 | Intermediate used for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-8853393-B2 | Intermediate for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2014-10-07 | — | — | US | disclosed |
| US-8853393-B2 | Intermediate for preparing tapentadol or analogues thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2014-10-07 | — | — | US | disclosed |
| US-20130231478-A1 | Novel Intermediate for Preparing Tapentadol or Analogues Thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2013-09-05 | — | — | US | disclosed |
| US-20130231478-A1 | Novel Intermediate for Preparing Tapentadol or Analogues Thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2013-09-05 | — | — | US | disclosed |
| EP-2617706-A1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2013-07-24 | — | — | EP | disclosed |
| WO-2013016840-A1 | NOVEL INTERMEDIATE USED FOR PREPARING TAPENTADOL OR ANALOGUES THEREOF | 安徽省新星药物开发有限责任公司 (CN) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011092719-A2 | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011080756-A1 | PROCESS FOR THE PREPARATION OF 1-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231478-A1 | Novel Intermediate for Preparing Tapentadol or Analogues Thereof | CYP1A2, CYP7A1, CYP3A5 | L3MBTL1 4322/4885MTNR1A 112/4885MTNR1B 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.